|
Video: What is a Stock Split?
|
|
XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rate) disease indications. Co.'s three primary product candidates are: XRx-008, a program for the treatment of autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury associated with severe virus infection and associated health consequences; and XRx-225, a program for the treatment of type 2 diabetic nephropathy. According to our XRTX split history records, XORTX Therapeutics has had 2 splits. | |
|
XORTX Therapeutics (XRTX) has 2 splits in our XRTX split history database. The first split for XRTX took place on November 10, 2023. This was a 1 for 9 reverse split, meaning for each 9 shares of XRTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 111.111111111111 share position following the split. XRTX's second split took place on November 14, 2023. This was a 1 for 9 reverse split, meaning for each 9 shares of XRTX owned pre-split, the shareholder now owned 1 share. For example, a 111.111111111111 share position pre-split, became a 12.3456790123457 share position following the split.
When a company such as XORTX Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the XRTX split history from start to finish, an original position size of 1000 shares would have turned into 12.3456790123457 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into XORTX Therapeutics shares, starting with a $10,000 purchase of XRTX, presented on a split-history-adjusted basis factoring in the complete XRTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/24/2021 |
|
End date: |
09/13/2024 |
|
Start price/share: |
$375.03 |
|
End price/share: |
$1.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.53% |
|
Average Annual Total Return: |
-83.50% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$47.19 |
|
Years: |
2.97 |
|
|
|
Date |
Ratio |
11/10/2023 | 1 for 9 | 11/14/2023 | 1 for 9 |
|
|